Harbeck N, Nitz UA, Christgen M, Kummel S, et al. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol 2023 Feb 21:JCO2201816. doi: 10.1200/JCO.22.01816.
PMID: 36809046